The purposes of this study were to determine the galectins Gal-1, Gal-3 and Gal-4 known to be overexpressed in pancreatic cancers as targets and to investigate a potential ligand tPA-derived peptide as receptor/ligand binding partner. This evidence concerns the gene GAL and familial pancreatic carcinoma.